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Second-line injectable drugsMutations causing mono and cross-resistance among amikacin, kanamycin and capreomycin of second-line in-
jectable drugs (SLIDs) namely are not well understood. We investigated 124 isolates ofMycobacterium tubercu-
losis for mutations within rrs, eis, tlyA and efﬂux pump (Rv1258c and Rv0194) genes involved in resistance
towards SLIDs. The distribution of mutations across these genes were signiﬁcantly different in strains with
mono-resistance or cross-resistance. A new mutation G878A was found in rrs gene, among strains with
capreomycin mono-resistant, or in strains with cross-resistance of capreomycin, kanamycin and amikacin. This
mutation was associated with the Euro-American X3 lineage (P b 0.0001). Mutations in the two efﬂux genes
Rv1258c and Rv0194 were conﬁned to strains with only capreomycin/amikacin/kanamycin cross-resistance.
We further investigated theminimum inhibitory concentration of capreomycin on isolates with newG878Amu-
tation ranging from 8 μg/mL to 64 μg/mL. Inclusion of G878A on new molecular assays could increase the sensi-
tivity of capreomycin resistance detection.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Drug resistant tuberculosis (TB) is a global threat and amajor public
health problem in several countries (WHO, 2014). World Health Orga-
nization (WHO) estimate that 480 000 new cases of multidrug resistant
(MDR)-TB and among them cases with extensively drug resistant
(XDR)-TB were reported at 9.0% worldwide (WHO, 2014). MDR-TB is
deﬁned as concurrent resistance to isoniazid and rifampicin, while
XDR-TB is MDR-TB plus resistance to one of the injectables plus resis-
tance to quinolones. Both MDR and XDR-TB are difﬁcult to treat and re-
quire the use of less effective second-line injectable drugs (SLIDs)which
are often associated with major side effects (Jain and Dixit, 2008). Ap-
propriate use of SLIDs of aminoglycosides (Maus et al., 2005a) is critical
to treatment of MDR-TB and prevention of XDR-TB cases (Georghiou
et al., 2012). XDR-TB is difﬁcult to treat than MDR-TB and require use
of capreomycin (CAP) in the intensive phase (Matteelli et al., 2014).
Since 2006, CAP has replaced amikacin (AMK) and kanamycin (KAN)
that forms the backbone regimen treatment of XDR-TB in South Africa
(Pietersen et al., 2015; Streicher et al., 2012).
CAP resistant strains can also be cross-resistant to AMK/KANgiven that
mutations conferring resistance are encoded by the rrs gene (Georghiouga@gmail.com (L. Malinga).
. This is an open access article underet al., 2012). Cross-resistance within SLIDs drugs has been reported back
in the early 1970s anduntil now, it has beendifﬁcult phenomenon to over-
come in treatment of XDR-TB (Tsukamura, 1969; Tsukamura andMizuno,
1975). To date, knowledge on mechanisms causing cross-resistance of in-
jectable drugs againstMycobacterium tuberculosis (M. tuberculosis) isolates
has been contradictory (Maus et al., 2005a). Understanding SLIDs cross-
resistance mechanisms at a molecular level should facilitate rapid detec-
tion of XDR-TB, due to limited treatment options (Reeves et al., 2013).
Moreover there is a high rate of CAP resistance in South African TB popu-
lation and this leads to poor treatment outcomes (Pietersen et al., 2015).
Mutations causing CAP resistance should be further investigated to in-
crease our efforts for rapid detection of XDR-TB.
The ribosomal (rrs) A1401G mutation is commonly associated with
cross-resistance between KAN, AMK, and CAP (Campbell et al., 2011;
Engstrom et al., 2012). Other mutations within the 16 S RNA (i.e.
G1484T, C517T, A514C) have also been implicated in cases of cross
and mono-resistance within the injectable drugs (Maus et al., 2005a).
Jugheli et al. found anassociation between theA1401Gmutation and re-
sistance to AMK and KANwithmoderately high speciﬁcity and sensitiv-
ity (Jugheli et al., 2009). However KAN resistance is often missed by
detection of A1401G and eis mutations are used to distinguish low
from high level KAN resistance (Zaunbrecher et al., 2009). Cross-
resistance to CAP is due to A1401G mutation, while the tlyAmutations
are involved in mono-resistance (Engstrom et al., 2011). Howeverthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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rrs 500 Forward:5′gatgacggccttcgggttgt3′ 123 bp (Honore and Cole,
1994)Reverse: 5′tctagtctgcccgtatcgcc3′









567 bp (Campbell et al., 2011)
Reverse: 5′gtcagctcatgcaaggtg3′
tlyA Forward:5′atgtcggataggccagctg3′ 555 bp (Campbell et al., 2011)
Reverse:5′actttttctacgcgcgccgtgc3′
Rv0194 Forward: 5′gcgacctacttgctgatgta3′ 700 bp This study
Reverse: 5′cgctggaactccagtgataa3′
Rv1258c Forward:5′cggcattcctgatcctgtt3′ 700 bp This study
Reverse: 5′cgtgtggtcggtgaagtatt3′
434 L. Malinga et al. / Diagnostic Microbiology and Infectious Disease 85 (2016) 433–437only 70–80% of CAP resistant isolates have A1401G mutation and this
suggests that there is still at least one mechanism of cross-resistance
to be discovered (Campbell et al., 2011; Pietersen et al., 2015). More-
over, association of certain genetic mutations to SLIDs needs further in-
vestigation, especially in genetically diverse strains. There is a large
variation of CAP minimal inhibitory concentrations (MIC) levels in Bei-
jing strains as compared to EuroAmerican lineage (Reeves et al., 2015).
Phenotypically resistant isolates that lack genetic mutations in
known regions lead to discordance in molecular assays (e.g. GenoType
MTBDRsl) which decrease their sensitivity (Engstrom et al., 2012;
Georghiou et al., 2012). Currently available molecular assays rely on
few mutations to accurately detect SLIDs resistance, especially in the
case of CAP drug. It has been shown that mutations within
M. tuberculosis transporter proteins lead to cross-resistance due to ef-
ﬂux pump mechanisms (Engstrom et al., 2011; Jugheli et al., 2009).
The G133C of Rv1258c efﬂux pump caused cross-resistance to amino-
glycosides (Reeves et al., 2013). Moreover, both Rv1258c and eis
genes are upregulated by whiB7 (Rv3197A) which might contribute to
cross-resistance of aminoglycosides (Reeves et al., 2013). Novel muta-
tions located in whiB7 lead to aminoglycosides cross-resistance in
M. tuberculosis (Reeves et al., 2013). A combination of mutations in dif-
ferent regions is important to accurately predict SLIDs cross-resistance
within pre-XDR and XDR-TB cases (Georghiou et al., 2012).We investi-
gated the association of phenotypic resistance cases of SLIDswithmuta-
tionswithin rrs, eis, tlyA and efﬂuxpumps (Rv1258c and Rv0194) genes.
We further determined the MIC resistance to CAP caused by the
detected G878A mutation.
2. Materials and methods
2.1. Bacterial strains
One hundred and twenty four culture isolates received from 2008 to
2012 and stored at the Medical Research Council TB laboratory in
Pretoria, South Africa were used. Isolates were selected based on pre-
XDR and XDR-TB criteria. The laboratory is a former Supranational TB
Reference Laboratory and has been previously involved in WHO proﬁ-
ciency testing schemes until 2013 (Mativandlela et al., 2013). Repeat
testing was done on all pre-XDR and XDR-TB isolates. The strains were
previously tested for AMK (1 μg/mL), KAN (5 μg/mL), CAP (2.5 μg/mL)
and oﬂoxacin (2 μg/mL) drugs using MGIT 960 system. The isolates
were classiﬁed as susceptible or resistant based on DST performed ear-
lier using standardized and quality assured methods.
2.2. Minimal inhibitory concentration determination
To determine the minimal inhibitory concentration (MIC 64–0.125
μg/mL) levels of AMK, KAN and CAP resistant isolates ofM. tuberculosis
strains based on conventional DST, a microplate alamarBlue assay
(MABA) was performed as described previously (Collins and Franzblau,
1997). Brieﬂy, the cultures were grown to mid-log phase on 7H9 OADC.
Once an OD of 0.6 was reached, 100 μL of the culturewas added to a solu-
tion of 98 μL of 7H9 OADC and 2 μL of CAP, AMK and KAN drug (Sigma
Aldrich). Alamar Blue reagent (Thermo Fischer, US) and 10% v/v Tween
80 of 25 μL eachwere added to thewells of themicroplate and further in-
cubated for 24 hours. After one day of incubation, resistancewas detected
by change of a blue to pink color. TheMICwas recorded as thewell with-
out color change at the lowest concentration. The H37Rv (ATCC 27294)
was used as negative control and was susceptible to all drugs tested.
2.3. DNA extraction, ampliﬁcation and sequencing
Crude DNA was isolated from MGIT cultures by boiling method.
Brieﬂy, 1000 μL of culture was transferred to a 1.5 mL Eppendorf tube
and centrifuged at 8000 ×g and supernatant discarded. The pellet was
re-suspended in 100 μL of deionised water, heat killed (20 minutes),sonicated (15 minutes) and supernatant transferred to a new tube
and stored at−20 °C until further processing. Genotype MTBDRslwas
run on all specimens as previously explained according to themanufac-
turer (Hain lifescience, Germany) (Hillemann et al., 2009). Discordant
isolates were ampliﬁed into seven genes by PCR using primers of rrs
(500, 900, and 1400), eis, tlyA, Rv0194 and Rv1258c genes synthesized
by integratedDNA technologies (Table 1). The 25 μL of the cocktail reac-
tion was made up of 11.5 μL of Hot Start mix (Kapa Biosystems, Cape
Town, South Africa), 1 μL each of sense and antisense primer, 7.5 μL dis-
tilled H2O (dH2O), and 2 μL of DNA. The ampliﬁcation protocol was per-
formed at 95 °C (15 minutes), followed by 30 cycles of 95 °C (30
seconds), 60 °C (30 seconds), 72 °C (30 seconds), with a ﬁnal step at
72 °C for 5 minutes. The PCR products were puriﬁed using puriﬁcation
kit (Qiagen, Hilden, Germany) according to themanufacturer’s protocol,
to remove unincorporated primers and nucleotides. Direct sequencing
of the genes was performed at Central Analytical Facility, Stellenbosch,
South Africa. These sequences were subjected to multiple sequence
alignment with H37Rv genome (GenBank accession number
NC_000962) using BioEdit software version 7.2 (http://www.mbio.
ncsu.edu/bioedit/bioedit.html).
2.4. Spoligotyping
The PCR products were ampliﬁed using primers purchased from
manufacturer (Ocimum Biosciences, India) and the procedure was per-
formed as previously described (Kamerbeek et al., 1997). After ampliﬁ-
cation, hybridization was performed on denatured DNA using a 43
spacer membrane. The direct repeat (DR) region was ampliﬁed by PCR
with primers derived from the DR sequences. The ampliﬁed PCR prod-
uct was hybridized to a set of 43 immobilized oligonucleotides on the
membrane. The products were detected by chemiluminescence
(Amersham Biosciences) and by exposure to X-ray ﬁlm (HyperﬁlmECL,
Amersham).The spoligotypes were reported by using a binary code as
previously described (Cowan et al., 2002).
2.5. Statistical analysis
The genetic data for each strainwas entered in aMicrosoft Ofﬁce Ac-
cess 2013 program. The genetic, genotype, and DST data sets were fur-
ther analyzed on Epi Info (version 3.5.1, 2008) and STATA 13.0
softwares. Fishers exact and chi square test were used to measure the
level of association.
2.6. Ethics approval
The permission to use the strains was sought from University of
Pretoria, Faculty of Health Sciences Research Ethics Committee (206/2012).
Table 2







AMK/KAN/CAP 18 (38) 29 (62) 0.02 47 (38)
AMK/KAN 2 (20) 8 (80) 0.001 10 (8)
AMK/CAP 6 (60) 4 (40) 0.37 10 (8)
KAN/CAP 3 (75) 1 (25) 0.15 4 (3)
AMK 2 (100) 0 (0) n/a 2 (2)
KAN 13 (65) 7 (35) 0.004 20 (16)
CAP 23 (74) 8 (26) 0.000 31 (25)
AMK= Amikacin; KAN = Kanamycin, CAP = Capreomycin.
n/a = non-applicable.
⁎ Pearson's chi-square.
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3.1. Level of drug resistance and association among pre-XDR-TB and XDR-TB
Of the 124 isolates, 47 (38%) were cross-resistant to AMK/KAN/CAP
drugs. Among those, 29 (62%) and 18 (38%) (62% vs 38%, p=0.02)
(Table 2) isolates belonged toXDR-TB andpre-XDR-TB cases respective-
ly. The AMK/KAN and AMK/CAP cross-resistant cases were both ten
(8%) while four cases (2%) were resistant to KAN/CAP drugs. The
AMK/KAN resistance was found in eight (80%) of XDR-TB strains,
while AMK/CAP resistance was found in 60% of pre-XDR-TB. The KAN/
CAP resistance was found in 75% of XDR-TB cases. Mono-resistant
cases of AMK, KAN and CAP drugs were two (2%), 20 (16%) and 31
(25%) respectively. Most of the 23 (74%) CAP and 13 (65%) KAN isolates
belonged to pre-XDR-TB. The Genotype MTBDRsl assay detected
A1401G mutation in 22 (47%) and one (10%) cases with AMK/KAN/
CAP and AMK/KAN resistance respectively. A combination of Genotype
MTBDRsl and DNA sequencing revealed 72 mutations within rrs, eis,
tlyA, Rv1258c, Rv0194 genes and increased sensitivity of both AMK/
KAN/CAP and AMK/KAN to 70% and KAN/CAP to 75%. Mutations in
KAN and CAP mono-resistant strains were detected by sequencing at a
frequency of 70% and 32% respectively (Table 3).
3.2. Molecular analysis of cross-resistance
For the analysis of AMK/KAN/CAP cross-resistance, we sequenced
seven genetic regions namely rrs (1400, 900, 500), eis, tlyA, Rv1258c
and Rv0194. We detected 33 (70%) AMK/KAN/CAP cross-resistant iso-
lates with mutations within these regions. The rrs A1401G was found
in 23 (49%), followed by rrsG878A in four isolates, eisC14T and C12T oc-
curredwithin two isolateswhile tlyA T257G change found in one isolate.
In another isolate while various mutations within the 500 region were
also found. One isolate (XDR) had a novel amino acid change of
Y177H within Rv1258c efﬂux pump.
We had 24 isolateswith cross-resistance to AMK/KAN and AMK/CAP
drugs (Table 2), ten (42%) among both AMK/KAN and AMK/CAP drugs,
and only four isolates with CAP/KAN resistance. We also sequenced
seven regions namely rrs (1400, 900, 500), eis, tlyA, Rv1258c andTable 3








rrs1400 23 1 1
rrs900 4 2 1
rrs500 1 0 1
eis 3 4 0
tlyA 1 0 0
Rv0194 0 0 2
Rv1258c 1 0 0
Total (%) 33 (45.8%) 7 (9.7%) 5 (6.9%)
*AMK= Amikacin; **KAN= Kanamycin, ***CAP = Capreomycin, #P b 0.000.Rv0194. The frequency of detected mutations were seven 7/10 (70%)
for AMK/KAN, ﬁve (50%) for AMK/CAP and three (75%) for KAN/CAP.
Four of the ten AMK/KAN resistant isolates had mutations of eis C14T
while another three had rrs mutations (A1401G, G878A and G837T).
The two of the ten isolates had T1238A and G878A that were detected
in the rrs regions of 1400 and 900 respectively. One isolate had various
mutations within rrs 500 region. Sequence analysis of Rv0194 efﬂux
pump revealed G170V and R83G novel mutations in two AMK/CAP
resistant isolates.
3.3. Molecular analysis of mono-resistance
Wehad a total of 53/124 (43%) isolateswithmono-resistant proﬁles
to CAP, KAN and AMK drugs (Tables 2 and 3). Most were resistant to
CAP, 31/53 (58%), 21/53 (37%) with KAN resistance while only two iso-
lates were AMK mono-resistant. The rrs (1400, 900, 500), eis, tlyA,
Rv1258c and Rv0194 mutations were found in 10/31 (32%) and 14/21
(70%) respectively for CAP and KAN mono-resistant isolates but none
in the AMK mono-resistant isolates (Table 3).
3.4. The association of G878A mutation and genotype
Spoligotyping revealed high genotypic diversity within 124 isolates.
The most prevalent families were of EuroAmerican lineage, S 44 (35%),
X2 5 (4%), X3 31 (25%), T 16 (13%) and LAM9 (7%),while Beijing 8 (7%),
Haarlem 7 (6%) and East Africa Indian 4 (3%) genotypes. The A1401G
mutation was found in 1 (4%) Beijing, 2 (9%) East African Indian, 7
(30%) S, 7 (30%) T1, 1 (4%) X2, 5 (22%) X3 distributed among all geno-
types. The new mutation of G878A was found in 16/31 of the
EuroAmerican X3 genotype compared to 5/88 in the rest of the geno-
types (95% conﬁdence interval: 5.98–58.94; P b 0.0001) (Table 4).
3.5. The G878A mutation on CAP MIC with different genotypes
To determine the phenotypic impact of G878A mutation on CAP
drug-resistance MIC levels of eight samples were established
(Table 5). Five isolates displayed MICs of moderate to high (8–64
μg/mL) resistance to CAP drugs belonging to EuroAmerican X3 geno-
type. Three isolates had theirMIC level at 32 μg/mL, twowere of S geno-
type. One isolate belonging to Beijing genotype had amoderateMIC at 8
μg/mL. The AMK/KAN cross-resistant isolates with C14T mutations
showedMIC levels of 4–16 μg/mL for both drugs. However, ﬁve isolates
had their MIC at 32 μg/mL and thus were independent of genotype.
4. Discussion
The study reports an association of rrs, eis, tlyA, Rv1258c and Rv0194
mutations with SLIDs cross and mono-resistant cases within XDR and
pre-XDR-TB. The mutations were distributed across all cases but those
in Rv1258c and Rv0194 were conﬁned to AMK/KAN/CAP and AMK/







0 0 1 26
1 9 5 22
1 0 3 6
1 0 5 13
0 1 0 2
0 0 0 2
0 0 0 1
3 (4.2%) 10 (13.9%) 14 (19.4%) 72
Table 4
Distribution of the G878A mutation among genotypes ofMycobacterium tuberculosis.
Phenotypic Resistance Strains harbouring G878A mutation EuroAmerican Lineage Non-EuroAmerican Lineage Total
X3 X2 S Beijing EIA
AMK/KAN/CAP 4 (18.2%) 3 1 4
CAP/KAN 1 (4.5%) 1 1
AMK/CAPC 1 (4.5%) 1 1
AMK/CAP 1 (4.5%) 1 1
CAP 10 (50%) 9 1 10
KAN 4 (18.2%) 2 1 1 4
Total (%) 21 (100%) 16 (75%) 1 (5%) 2 (10%) 1 (5%) 1 (5%) 21 (100%)
AMK= Amikacin; KAN = Kanamycin, CAP =Capreomycin.
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A1401G mutation with AMK/KAN/CAP cross-resistance (Campbell
et al., 2011; Engstrom et al., 2012; Jugheli et al., 2009; Maus et al.,
2005a) but 20% of isolates were found to lack this mutation
(Georghiou et al., 2012; Liu et al., 2013).We combinedmutationswithin
eis, rrs, tlyA, Rv1258c and Rv0194 to report a sensitivity of 70% in predic-
tion of cross-resistance. Jugheli et al. found higher sensitivities by using
A1401G mutation on its own, but most of these investigators’ isolates
belonged to Beijing genotype (Jugheli et al., 2009). This mutation was
found to have a signiﬁcant association with the Beijing genotype as
compared to non-Beijing genotypes (Miotto et al., 2012). We found
high genotypic diversity among cross-resistant isolates, most of them
belonged to the EuroAmerican family, which could explain our lower
sensitivity. The EuroAmerican family has signiﬁcantly higher phyloge-
netic diversity than Beijing genotype (Casali et al., 2014). The A1401G
mutation have been found among AMK/CAP and KAN/CAP resistant
strains (Said et al., 2012; Sirgel et al., 2012), but we found the mutation
in only one isolate with AMK/KAN resistance.
The eis C12Tmutation was found in one isolate with AMK/KAN/CAP
cross-resistance, despite it been shown to be present in KAN susceptible
isolates (Zimenkov et al., 2013). Others have conﬁrmed that this muta-
tion has a low MIC level of KAN at 5 μg/mL (Gikalo et al., 2012; Huang
et al., 2011; Tukvadze et al., 2014).Table 5
The effect of mutations on minimal inhibitory concentrations of second-line drugs with
different genotypes.
Strain DST proﬁle Mutation KAN MIC AMK MIC CAP MIC Genotype
Cross-resistance
361 AMK/KAN/CAP C12T 8 8 16 X3
429 AMK/KAN/CAP G878A 4 8 8 Beijing
102 AMK/KAN/CAP C14T 16 16 64 S
S358 AMK/KAN/CAP Y177H 16 16 32 H
Dual-resistance
908 AMK/KAN C14T 8 16 ND X3
121 AMK/KAN C14T 8 8 ND X3
1989 AMK/KAN C14T 16 16 ND S
151 AMK/KAN C14T 4 4 ND X3
Mono-resistance
1799 KAN G985T 4 ND ND S
887 KAN G37T 8 ND ND S
671 KAN G37T 4 ND ND T1
211 KAN A1219T 16 ND ND T1
B107 KAN C517T 4 ND ND T1
591 CAP G878A ND ND 32 S
569 CAP G878A ND ND 32 S
49 CAP G878A ND ND 32 X3
94 CAP G878A ND ND 8 X3
212 CAP G878A ND ND 32 X3
1040 CAP G878A ND ND 32 X3
33 CAP G878A ND ND 64 S
S85 CAP T257G ND ND 8 S
H37Rv Sensitive WT 2 1 1
AMK-Amikacin, KAN-Kanamycin, CAP-Capreomycin, MIC-Minimal Inhibitory Concentra-
tions, ND-not done.The eis C14T gene is associated with AMK/KAN cross-resistance
(Campbell et al., 2011; Rodwell et al., 2014) and including it in molecu-
lar assays increased the sensitivity for SLIDs resistance, as was shown in
a new version of the Genotype MTBDRsl (v2.0) (Tagliani et al., 2015).
The eis C14T mutation is regarded as a very good marker for KAN resis-
tance and causes very high levels of KAN resistance (MICs 16 to 32
μg/mL) (Gikalo et al., 2012). Our results conﬁrm this mutation’s pres-
ence in KAN resistant isolates. Strains harbouring this mutation are
however still susceptible to CAP (Zimenkov et al., 2013). The eis G37T
and C12T mutations are considered as borderline or low-level to KAN
drug (Gikalo et al., 2012). Mutations within eis gene increases the viru-
lence ofM. tuberculosis that are thought to be responsible for preserva-
tion of bacterial ﬁtness, and could be the reason for the extensive
transmission of drug-resistant TB strains in Russia (Casali et al., 2014).
Absence of AMK/CAP cross-resistance in strains harbouring mutations
in the eis gene has been recently demonstrated (Casali et al., 2014;
Gikalo et al., 2012). Our study also conﬁrms that none of the eismuta-
tions are found in AMK/CAP cross-resistant isolates.
The Y177H mutation within Rv1258c found in one XDR-TB isolate
with AMK/KAN/CAP cross-resistance. The Rv1258c is a stable gene re-
gion (Ainsa et al., 1998) and appearance of a mutation could lead to
higher efﬂux pump activity, as suspected among isolates with this
cross-resistance (Albert et al., 2010; Reeves et al., 2013). Interestingly
two mutations within Rv0194 of R83G and G170V were detected in
pre-XDR-TB and XDR-TB isolates respectively. Similar to other investi-
gators we found mutations within Rv0194 in an XDR-TB strain that
lacked known mutations (Ilina et al., 2013; Liu et al., 2014).
The C517Tmutation is contradictory in KAN resistance and has been
found in isolates with an additional eis of C14T mutation (Jnawali et al.,
2013). The rrs 500mutations are usually found in isolates that are resis-
tant to KAN but at a low frequency (Jugheli et al., 2009; Maus et al.,
2005a). The G878A mutation has not yet been reported in KAN/CAP
cross-resistance. The KAN/CAP cross-resistant isolates usually lack
known mutations however changes within whiB7 and Rv3728 have
been reported (Casali et al., 2012; Casali et al., 2014; Du et al., 2013).
Capreomycin mono-resistance is associated with mutations in rrs
and tlyA genes (Georghiou et al., 2012; Maus et al., 2005b) but tlyAmu-
tations are regarded asweakmarkers due the diversity ofmutations and
their appearance in susceptible isolates as well (Engstrom et al., 2011;
Engstrom et al., 2012; Sowajassatakul et al., 2014).
We detected the rrs G878A mutation in 21/124 (17%) resistant iso-
lates and of those 9/21 (43%)were resistant to CAP. The rrsG878Amuta-
tion has been previously been detected and its function not well
understood (Daum et al., 2012). Our CAP MIC data ranges between
8–64 μg/mL on isolates harbouring this mutation, while there might be
an association with EuroAmerican X3 lineage. Wewere able to show as-
sociation of G878A with EuroAmerican X3 lineage (Pb0.0001). The
G878A mutation may be a novel mutation for CAP resistance and an in-
trinsic resistant marker for X3 genotype. Most recently, Reeves et al. also
mentioned that a CAPMIC of 8 μg/mLwith nomutations within rrs gene
could be due to an unidentiﬁed mechanism (Reeves et al., 2015).
Discordance of CAP resistance between molecular and phenotypic
methods is common due to unreliable critical concentrations and lack
437L. Malinga et al. / Diagnostic Microbiology and Infectious Disease 85 (2016) 433–437of consistent molecular markers (Reeves et al., 2015). This limitation of
CAP phenotypic testing highlights the importance of molecular diagno-
sis of CAP resistance. We used theWHO recommended critical concen-
trations of 2.5 μg/mL inMGIT 960, similar discordant results were found
by others (Kam et al., 2010; Rodwell et al., 2014). A higher critical con-
centration of 10 μg/mL could clearly distinguish between resistant and
susceptible CAP isolates (Fitzwater et al., 2013; Trollip et al., 2014).
In conclusion, our study shows an association of certain genetic
markers with different SLIDs cross-resistant patterns. The G878A muta-
tion predominantly found in strains of the EuroAmerican X3 family is a
new mechanism of resistance to CAP. The inclusion of this mutation in
diagnostic assays may increase the sensitivity for SLIDs resistance. Infor-
mation on predominant genotypes andmutations in regions can further-
more be used when developing region-speciﬁc assays. Most of the SLIDs
cross-resistance was associated with XDR-TB and this highlights the
need to increase the sensitivity of diagnostic assays. A combination ofmu-
tations is required to improve the detection of SLIDs cross-resistance.
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